SEH1L: A Potential Drug Target and Biomarker for the Treatment of Sleep-Disordered Breathing

Target Name: SEH1L

NCBI ID: G81929

SEH1L

SEH1L: A Potential Drug Target and Biomarker for the Treatment of Sleep-Disordered Breathing

Sleep-disordered breathing (SDB) is a common sleep disorder that affects millions of people worldwide, characterized by the disruption of normal breathing during sleep, leading to reduced sleep efficiency and increased fatigue. SDB is associated with various respiratory and cardiovascular diseases, including cardiovascular disease, diabetes, and respiratory failure. Despite its significant impact on quality of life, SDB remains a refractory disease with limited treatment options.

The protein SEH1L, which stands forSec13-like protein, is a potential drug target and biomarker for the treatment of SDB. SEH1L is a highly conserved protein that is expressed in various tissues and organs, including brain, heart, lungs, and muscles. It is characterized by a distinct N-terminus, a unique feature that is found in only a small number of proteins.

SEH1L functions as a negative regulator of the Paralogue-promoting gene (PPG), which is responsible for the production of slow-twitch muscle fibers that are critical for generating force during physical activity. PPG is a master gene that regulates muscle fibers by controlling the expression of genes that encode the slow-twitch and fast-twitch fibers. SEH1L plays a crucial role in the regulation of PPG, as it interacts with the upstream gene for the PPG gene, known as PPL.

SEH1L has been shown to be a unique protein that is expressed in the heart, lungs, and brain, and it has been identified as a potential drug target for SDB. Several studies have demonstrated that SEH1L is involved in the regulation of SDB, including increased expression of SEH1L in the lungs and heart during the transition from wakefulness to sleep and increased SEH1L-containing fibers in the diaphragm muscle during inspiration.

In addition to its potential therapeutic impact, SEH1L is also a valuable biomarker for the diagnosis and monitoring of SDB. The identification of SEH1L as a potential drug target has led to a greater understanding of the underlying mechanisms of SDB, which may ultimately lead to the The development of new, more effective treatments for this disease.

SEH1L has been shown to be involved in the regulation of various physiological processes that are important for SDB, including breathing patterns, muscle contractions, and oxygen utilization. Several studies have demonstrated that SEH1L interacts with other proteins that are also involved in SDB, including the transcription factor, peroxisome proliferator-activated receptor (PPAR), and the G protein-coupled receptor (GPCR).

SEH1L has also been shown to be involved in the regulation of inflammation, which is a key player in the development of SDB. Several studies have demonstrated that SEH1L is involved in the regulation of pro-inflammatory cytokine production and in the modulation of immune cell function . These findings suggest that SEH1L may play an important role in the pathogenesis of SDB and that it may be a useful biomarker for the diagnosis and monitoring of this disease.

In conclusion, SEH1L is a protein that has significant potential as a drug target and biomarker for the treatment of SDB. Its unique function as a negative regulator of PPG and its expression in various tissues and organs make it an attractive target for drug development. Further research is needed to fully understand the role of SEH1L in the regulation of SDB and to develop new treatments for this disease.

Protein Name: SEH1 Like Nucleoporin

Functions: Component of the Nup107-160 subcomplex of the nuclear pore complex (NPC). The Nup107-160 subcomplex is required for the assembly of a functional NPC. The Nup107-160 subcomplex is also required for normal kinetochore microtubule attachment, mitotic progression and chromosome segregation. This subunit plays a role in recruitment of the Nup107-160 subcomplex to the kinetochore

The "SEH1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEH1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets